Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma 12Lymphoma, Large B-Cell, Diffuse 12Sarcoma, Ewing 4Lymphoma, B-Cell 4Recurrence 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Osteosarcoma 3Neurofibrosarcoma 3Lymphoma, Non-Hodgkin 3Liposarcoma 3Hodgkin Disease 3Fibrosarcoma 3Sarcoma, Synovial 2Sarcoma, Clear Cell 2Rhabdomyosarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neuroblastoma 2Nerve Sheath Neoplasms 2Neoplasms, Germ Cell and Embryonal 2Lymphoma, Follicular 2Lymphoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Histiocytoma, Angiomatoid Fibrous 2Hemangiosarcoma 2Granuloma, Plasma Cell 2Desmoplastic Small Round Cell Tumor 2Dermatofibrosarcoma 2Chondrosarcoma, Extraskeletal Myxoid 2Burkitt Lymphoma 2

Interventions

Cyclophosphamide 51fludarabine 37Dexamethasone 35venetoclax 30pembrolizumab 25Rituximab 20pomalidomide 18Lenalidomide 17Gemcitabine 17fludarabine phosphate 15Etoposide 14Cytarabine 13daratumumab 12carfilzomib 11Temozolomide 11Injections 10Calcium Dobesilate 10glofitamab 9Nivolumab 9Cisplatin 9Bortezomib 9Azacitidine 9selinexor 8Vincristine 8Immunotherapy, Adoptive 8obinutuzumab 7cemiplimab 7Drug Therapy 7Carboplatin 7zanubrutinib 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recurrence × Ifosfamide × 1 year × Clear all
NCT05533775 2026-06-03

iMATRIX GLO

Hoffmann-La Roche

Phase 1/2 Recruiting
65 enrolled

Recurrence

NCT00864318 2026-04-14

TICE

Institut Claudius Regaud

Phase 2 Completed
101 enrolled

Neoplasms, Germ Cell and Embryonal, Recurrence

NCT03458260 2026-03-10

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

The Lymphoma Academic Research Organisation

Phase 2 Completed
74 enrolled
Lymphoid

Recurrence, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡